ALMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alumis Inc (ALMS) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The technical indicators are bullish, insider buying is strong, and analysts maintain positive ratings with increased price targets. Despite weak financial performance, the company's lead drug has strong competitive positioning and potential catalysts in upcoming trials.
The technical indicators for ALMS are bullish. The MACD is positive and expanding, moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200), and the stock is trading above key support levels. RSI is neutral at 69.014, indicating no overbought or oversold conditions.
Insider buying has increased significantly by 586.17% over the last month.
Analysts have raised price targets, with Oppenheimer increasing it to $55 and maintaining an Outperform rating.
The company's lead drug, envudeucitinib, has shown strong efficacy and safety in Phase 3 trials, with potential catalysts in upcoming Phase 2 and Phase 3 readouts.
Financial performance is weak, with a net income loss of -$92.93M in Q4 2025 and EPS declining by -48.85% YoY.
The oral psoriasis drug market is becoming increasingly competitive, as noted by H.C. Wainwright.
In Q4 2025, revenue remained flat YoY at $1.93M, while net income dropped to -$92.93M (-1.93% YoY). EPS declined significantly by -48.85% YoY to -$0.89. Gross margin remained stable at 100%.
Analysts are generally bullish on ALMS. Raymond James and Oppenheimer maintain strong buy/outperform ratings, citing competitive advantages for envudeucitinib. Recent price targets have been raised to $55 (Oppenheimer) and $38 (Morgan Stanley), though H.C. Wainwright lowered its target to $25 due to increased competition.
